|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association with the risk of HCC was observed for the DraI polymorphism of CYP2E1 or for the GSTM1-null genotype.
|
7557094 |
1995 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The carrier state of one copy of the c2 CYP2E1 gene increases the risk of hepatoma in previously regular ethanol users with chronic liver disease.
|
8977352 |
1996 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, the influence of CYP2E1, GSTM1, or the combined at-risk genotype on the risk of hepatocellular carcinoma in smokers is briefly discussed.
|
9255556 |
1997 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that there is a lack of association of the polymorphisms of CYP2E1 with the risk of HCC in humans.
|
9180139 |
1997 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CYP2E1 5'-flanking regions of the human (-3712 bp to +10 bp) and rat (-3685 bp to +28 bp) genes were ligated in front of a luciferase reporter gene and transfected into rat hepatoma Fao and human hepatoma B16A2 cells.
|
10491286 |
1999 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast to results with HepG2 cells expressing CYP2E1, no increase in GCS-HS mRNA was found with a HepG2 cell line engineered to express human cytochrome P450 3A4.
|
10748080 |
2000 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We developed a human hepatoma cell model that faithfully reproduces the responsiveness of the CYP2E1 gene to IL-4 at least in part through transcriptional activation, upon treatment with 150 U/ml of IL-4.
|
11101004 |
2000 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found 8 mRNAs underexpressed in primary HCC tissues in 20 patients in higher percentages than found in previous studies, including 18 cases (90%) for aldolase B (ALDOB), 15 cases (75%) for carbamyl phosphate synthetase 1 (CPS1), albumin (ALB), plasminogen (PLG), and EST 51549, 13 cases (65%) for cytochrome P450 subfamily 2E1 (CYP2E1), 12 cases (60%) for human retinol-binding protein 4 (RBP4), and 11 cases (55%) for human organic anion transporter C (OATP-C) gene.
|
12143053 |
2002 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that whereas peanut intake, water sources as well as genetic polymorphisms in ALDH2 and CYP2E1 do not significantly correlate with the risk of HCC, HBV infection is a main risk factor, and dietary items rich in protein, especially fresh fish, might protect against the risk of HCC in Haimen, China.
|
12495467 |
2002 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The high-activity CYP2E1 c2 allele was underrepresented among HCC patients with respect to other HCV categories, including cirrhosis.
|
12569554 |
2003 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
We examined changes in heme metabolism by analyzing gene expression of the non-specific delta-aminolevulinate synthase (ALAS-N), and heme oxygenase-1 (HO-1), the rate limiting enzyme in heme synthesis and catabolism, respectively, in the human hepatoma cell line HLE/2E1, in which CYP2E1 was overexpressed by transfection of its expression vector.
|
12469218 |
2003 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of genetic polymorphisms for glutathione S-transferase ( GST) M1, GSTT1, GSTP1-1( GSTP1), cytochrome P450 2E1 ( CYP2E1) and aldehyde dehydrogenase 2 ( ALDH2) on the risk of hepatocellular carcinoma (HCC) was observed in 78 Japanese patients with HCC and 138 non-cancer hospital controls.
|
12759747 |
2003 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ALDH2 and CYP2E1 polymorphisms may modify the risk of development of HCC against the background of LC in the Japanese.
|
12940444 |
2003 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC.
|
15162526 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC.
|
15162526 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human hepatoma HepG2 cells with transduced CYP2E1 (E47 cells) were used as a model to generate ROS through CYP2E1-mediated ethanol metabolism.
|
15449375 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC.
|
15162526 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review describes some of the biochemical and toxicological properties of CYP2E1, especially as it relates to alcohol metabolism and toxicity and the establishment of human hepatoma HepG2 cell lines that overexpress human CYP2E1.
|
14744237 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among the 27 CYPs, levels of 7 (CYP2B6, CYP-IIC, CYP2C9, CYP2C19, CYP3A5, CYP4F3 and CYP27A1) were significantly lower and levels of 2 (CYP2E1 and CYP4F2) were slightly lower in HCC with venous invasion than in HCC without venous invasion.
|
16077914 |
2005 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
The aim of this study was to determine whether hepatitis C virus core protein and alcohol-inducible cytochrome P450 2E1 contribute to reactive oxygen species production and cytotoxicity in human hepatoma cells.
|
15633127 |
2005 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HCC cell line HepG2 was infected with Ad-CYP2E1 to enhance the expression of CYP2E1, followed by treatment with low toxic dose of recombinant human Fas ligand (FasL, 0.5 ng/ml) in the presence of Actinomycin D (Act D, 125 ng/ml).
|
18497573 |
2008 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.
|
19643819 |
2009 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data showed that TSA selectively induced CYP2E1 in four studied human hepatocellular carcinoma (HCC) cell lines (Huh7, PLC/PRF/5, Hep3B and HepG2), but not in normal primary human hepatocytes.
|
20404016 |
2010 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis indicated that CYP2E1 Pst I/Rsa polymorphism was not associated with HCC risk, while the interaction between Pst I/Rsa polymorphism and alcohol consumption increased the risk of HCC.
|
22249978 |
2012 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Compared to controls, Cyp2E1 rsaI variant c2 genotype increased the risk of HBV related liver disease severity by 2.68 fold, the highest for HCC cases (3.981 folds, p=0.106); and was associated with higher histology activity index (HAI) (p<0.001) in CHBV patients.
|
23454624 |
2013 |